Carbapenem-resistant Enterobacterales in patients with bacteraemia at tertiary academic hospitals in South Africa, 2019 - 2020: An update
DOI:
https://doi.org/10.7196/SAMJ.2022.v112i8.16351Keywords:
carbapenem-resistant EnterobacteralesAbstract
Background. The emergence of carbapenem-resistant Enterobacterales (CRE) has become a serious and significant public health threat worldwide, owing to the limited antimicrobial therapy options, and the elevated mortality rates associated with these infections.
Objectives. To present an update on the epidemiology of CRE bloodstream infections among hospitalised patients reported under the Group for Enteric, Respiratory and Meningeal Diseases Surveillance in South Africa (GERMS-SA) between January 2019 and December 2020. Methods. Patients of all ages with CRE bacteraemia were included and isolates, when available, were sent to the reference laboratory for confirmatory testing and molecular characterisation. Multivariable logistic regression analysis was performed to assess factors associated with in-hospital mortality.
Results. We included 2 144 patients with CRE bacteraemia with a median age of 33 (interquartile range 1 - 51) years, of whom 1 145 (54.2%) were male. Klebsiella pneumoniae accounted for 79.8% of infections (n=863/1 082), of which 89.5% (n=611/683) were healthcare associated (HA). The most common carbapenemase genes were carbapenem-hydrolysing oxacillinase-48 (blaOXA-48-like) (76.8%; n=761/991), New Delhi metallo-β-lactamase (blaNDM) (21.1%; n=209/991) and Verona integron-encoded metallo-β-lactamase (blaVIM) (1.3%; n=13/991). None of the screened isolates with a colistin minimum inhibitory concentration >2 μg/mL harboured the mobilised colistin resistance (mcr)-1 to mcr-5 genes. The crude in-hospital mortality rate was 36.6% (n=377/1 029). Patients aged ≥60 years (v. 1.6 - 9 years) (adjusted odds ratio (aOR) 4.53; 95% confidence interval (CI) 2.21 - 9.28), those with comorbidities (diabetes, malignancy, renal and/or cardiovascular failure) (aOR 1.72; 95% CI 1.17 - 2.52), those with altered mental state (aOR 5.36; 95% CI 3.21 - 8.92) and those with previous antimicrobial use (aOR 1.88; 95% CI 1.27 - 2.77) had increased odds of in-hospital mortality.
Conclusion. The epidemiology of CRE bloodstream infections remained similar compared with the previous surveillance report. Most infections were HA and caused by OXA-48-like carbapenemase-producing K. pneumoniae with no plasmid-mediated colistin resistance. Standard infection control measures should be strengthened.
References
Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections caused by carbapenem-resistant Enterobacteriaceae: An update on therapeutic options. Front Microbiol 2019;10:80. https://doi. org/10.3389/fmicb.2019.00080
Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: Here is the storm! Trends Mol Med 2012;18(5):263-272. https://doi.org/10.1016/j.molmed.2012.03.003
Van Duin D, Arias CA, Komarow L, et al. Molecular and clinical epidemiology of carbapenem- resistant Enterobacterales in the USA (CRACKLE-2): A prospective cohort study. Lancet Infect Dis 2020(6);20:731-741. https://doi.org/10.1016/S1473-3099(19)30755-8
World Health Organization. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. Geneva: WHO, 2017. http://apps.who.int/iris/bitstream/handle/10665/259462/9789241550178-eng. pdf;jsessionid=623130C9C3DE356707C020ED2F5D2CC0?sequence=1 (accessed 8 June 2021).
Castanheira M, Doyle TB, Collingsworth TD, Sader HS, Mendes RE. Increasing frequency of OXA- 48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/ vaborbactam and comparators against these isolates. J Antimicrob Chemother 2021;76(12):3125-3134. https://doi.org/10.1093/jac/dkab306
Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 2015;59(10):5873-5884. https:// doi.org/10.1128/AAC.01019-15
Brink A, Coetzee J, Clay C, et al. The spread of carbapenem-resistant Enterobacteriaceae in South Africa: Risk factors for acquisition and prevention. S Afr Med J 2012;102(7):599-601. https://doi. org/10.7196/SAMJ.5789
Brink AJ, Coetzee J, Clay CG, et al. Emergence of New Delhi metallo-beta-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa. J Clin Microbiol 2012;50(2):525-527. https://doi.org/10.1128/JCM.05956-11
Brink AJ, Coetzee J, Corcoran C, et al. Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract. J Clin Microbiol 2013;51(1):369-372. https://doi.org/10.1128/JCM.02234-12
Lowman W, Sriruttan C, Nana T. NDM-1 has arrived: First report of carbapenem resistance mechanism in South Africa. S Afr Med J 2011;101(12):873-875. https://doi.org/10.7196/SAMJ.5329
Perovic O, Britz E, Chetty V, Singh-Moodley A. Molecular detection of carbapenemase-producing genes in referral Enterobacteriaceae in South Africa: A short report. S Afr Med J 2016;106(10):975-977. https://doi.org/10.7196/SAMJ.2016.v106i10.11300
Singh-Moodley A, Perovic O. Antimicrobial susceptibility testing in predicting the presence of carbapenemase genes in Enterobacteriaceae in South Africa. BMC Infect Dis 2016;16(1):536-546. https://doi.org/10.1186/s12879-016-1858-7
Perovic O, Ismail H, Quan V, et al. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018. Eur J Clin Microbiol Infect Dis 2020;39(7):1287-1294. https://doi.org/10.1007/s10096-020-03845-4
Lowe M, Kock MM, Coetzee J, et al. Klebsiella pneumoniae ST307 with blaOXA-181, South Africa, 2014 - 2016. Emerg Infect Dis 2019;25(4):739-747. https://doi.org/10.3201/eid2504.181482
Strydom KA, Chen L, Kock MM, et al. Klebsiella pneumoniae ST307 with OXA-181: Threat of a high-risk clone and promiscuous plasmid in a resource-constrained healthcare setting. J Antimicrob Chemother 2020;75(4):896-902. https://doi.org/10.1093/jac/dkz550
Singh-Moodley A, Perovic O. Phenotypic and genotypic correlation of carbapenememase-producing Enterobacteriaceae and problems experienced in routine screening. S Afr Med J 2018;108(6):495-501. https://doi.org/10.7196/SAMJ.2018.v108i6.12878
Pitout JDD, Peirano G, Kock MM, Strydom KA, Matsumura Y. The global ascendency of OXA-48-type carbapenemases. Clin Microbiol Rev 2019;33(1):e00102-19. https://doi.org/10.1128/CMR.00102-19
Tangden T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: Clinical perspectives on detection, treatment and infection control. J Intern Med 2015;277(5):501-512. https://doi.org/10.1111/joim.12342
Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: Epidemiology, genetic context, treatment options and detection methods. Front Microbiol 2016;7:895. https://doi.org/10.3389/fmicb.2016.00895
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100. Wayne, Pa.: CLSI, 2019.
Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, Pa.: CLSI, 2020.
Rebelo AR, Bortolaia V, Kjeldgaard JS, et al. Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 for surveillance purposes. Euro Surveill 2018;23(6):17-00672. https://doi.org/10.2807/1560-7917.ES.2018.23.6.17-00672
Zou H, Xiong SJ, Lin QX, Wu ML, Niu SQ, Huang SF. CP-CRE/non-CP-CRE stratification and CRE resistance mechanism determination help in better managing CRE bacteremia using ceftazidime- avibactam and aztreonam-avibactam. Infect Drug Resist 2019;12:3017-3027. https://doi.org/10.2147/ IDR.S219635
Tamma PD, Goodman KE, Harris AD, et al. Comparing the outcomes of patients with carbapenemase- producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis 2017;64(3):257-264. https://doi.org/10.1093/cid/ciw741
Ambretti S, Bassetti M, Clerici P, et al. Screening for carriage of carbapenem-resistant Enterobacteriaceae in settings of high endemicity: A position paper from an Italian working group on CRE infections. Antimicrob Resist Infect Control 2019;8:136. https://doi.org/10.1186/s13756-019-0591-6
Glasner C, Albiger B, Buist G, et al. Carbapenemase-producing Enterobacteriaceae in Europe: A survey among national experts from 39 countries, February 2013. Euro Surveill 2013;18(28):20525. https://doi. org/10.2807/1560-7917.es2013.18.28.20525
Zhang R, Liu L, Zhou H, et al. Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae (CRE) strains in China. EBioMedicine 2017;19:98-106. https://doi.org/10.1016/j.ebiom.2017.04.032
Group for Enteric, Respiratory and Meningeal Diseases Surveillance in South Africa (GERMS-SA). Annual surveillance report. 2020. https://www.nicd.ac.za/wp-content/uploads/2022/02/2020-GERMS-SA-Annual-Review.pdf (accessed 1 December 2021).
Poirel L, Bonnin RA, Nordmann P. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. Antimicrob Agents Chemother 2012;56(1):559-562. https://doi.org/10.1128/AAC.05289-11
National Department of Health, South Africa. Practical manual for implementation of the national infection prevention and control strategic framework. October 2021. https://www.knowledgehub.org.za/system/files/elibdownloads/202110/National%20Infection%20Prevention%20and%20Control%20 Practical%20Manual%20%28Web%20version%29.pdf (accessed 1 December 2021).
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
